Literature DB >> 3276312

Purification and characterization of placental protein 5.

R Bützow1, M L Huhtala, H Bohn, I Virtanen, M Seppälä.   

Abstract

This report describes the purification of placental protein 5, PP5, from the human placenta by two affinity chromatography steps, the first with Heparin-Sepharose and the second with Sepharose-linked monoclonal anti-PP5 antibody. The final purification is achieved by reversed-phase high performance liquid chromatography. In SDS-polyacrylamide gel electrophoresis under reducing or nonreducing conditions, PP5 purified in this study migrates as one major band at 36 kD. The previously purified PP5 is more heterogeneous: under nonreducing conditions it migrates at 30 kD and, after reduction, it gives three bands at 16.8 kD, 18.3 kD, and 19.0 kD. In Western blot analysis, both purified proteins react with polyclonal and monoclonal anti-PP5 antibodies. Three N-terminal amino acid sequences are obtained for the previously purified PP5, whereas the N-terminal of PP5 purified in this study is blocked. These results suggest that PP5 previously purified in the absence of protease inhibitors, does not represent the native form of PP5. Computer comparison of the obtained amino acid sequences revealed no significant homology to known protein sequences.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3276312     DOI: 10.1016/0006-291x(88)90546-3

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis.

Authors:  M P Herman; G K Sukhova; W Kisiel; D Foster; M R Kehry; P Libby; U Schönbeck
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

2.  Prognostic significance of tissue factor pathway inhibitor-2 in pancreatic carcinoma and its effect on tumor invasion and metastasis.

Authors:  Zhigang Tang; Guangyong Geng; Qiang Huang; Geliang Xu; Hejie Hu; Jiong Chen; Jiansheng Li
Journal:  Med Oncol       Date:  2009-09-10       Impact factor: 3.064

3.  Tissue factor pathway inhibitor-2 inhibits the growth and invasion of hepatocellular carcinoma cells and is inactivated in human hepatocellular carcinoma.

Authors:  Yong Xu; Xiaolin Qin; Jinjing Zhou; Zhiguang Tu; Xiao Bi; Wuxian Li; Xiaoqing Fan; Yi Zhang
Journal:  Oncol Lett       Date:  2011-07-05       Impact factor: 2.967

4.  Methylation-induced downregulation of TFPI-2 causes TMPRSS4 overexpression and contributes to oncogenesis in a subset of non-small-cell lung carcinoma.

Authors:  Junko Hamamoto; Kenzo Soejima; Katsuhiko Naoki; Hiroyuki Yasuda; Yuichiro Hayashi; Satoshi Yoda; Sohei Nakayama; Ryosuke Satomi; Hideki Terai; Shinnosuke Ikemura; Takashi Sato; Daisuke Arai; Kota Ishioka; Keiko Ohgino; Tomoko Betsuyaku
Journal:  Cancer Sci       Date:  2014-12-08       Impact factor: 6.716

5.  Promoter hypermethylation and silencing of tissue factor pathway inhibitor-2 in oral squamous cell carcinoma.

Authors:  Yi-Hui Lai; Ru-Yin He; Jian-Liang Chou; Michael W-Y Chan; Yu-Fen Li; Chien-Kuo Tai
Journal:  J Transl Med       Date:  2014-09-02       Impact factor: 5.531

6.  Tissue Factor Pathway Inhibitor-2 Gene Polymorphisms Associate With Coronary Atherosclerosis in Chinese Population.

Authors:  Jia Yu; Rong-Le Liu; Xin-Ping Luo; Hai-Ming Shi; Duan Ma; Jun-Jie Pan; Huan-Chun Ni
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.